

1 **CXCR4 and MIF are required for neutrophil extracellular trap release**  
2 **triggered by *Plasmodium*-infected erythrocytes.**

3

4 **Authors and affiliations**

5

6 Danielle S. A. Rodrigues<sup>1</sup>, Elisa B. Prestes<sup>1</sup>, Leandro de Souza Silva<sup>2</sup>, Ana  
7 Acácia S. Pinheiro<sup>2</sup>, Jose Marcos C. Ribeiro<sup>3</sup>, Alassane Dicko<sup>4</sup>, Patrick E.  
8 Duffy<sup>5</sup>; Michal Fried<sup>5</sup>, Ivo M. B. Francischetti<sup>3</sup>, Elvira M. Saraiva<sup>6</sup>, Heitor A.  
9 Paula Neto<sup>7\*</sup>, and Marcelo T. Bozza<sup>1\*</sup>.

10

11 <sup>1</sup>Laboratório de Inflamação e Imunidade, Departamento de Imunologia, Instituto  
12 de Microbiologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro,  
13 Brazil;

14 <sup>2</sup>Laboratório de Sinalização Celular, Instituto de Biofísica Carlos Chagas Filho,  
15 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;

16 <sup>3</sup>Section of Vector Biology, Laboratory of Malaria and Vector Research,  
17 National Institute of Allergy and Infectious Diseases, 12735 Twinbrook Parkway  
18 Room 3E28, Rockville, MD, 20852, USA.

19 <sup>4</sup>Malaria Research & Training Center, Faculty of Medicine, Pharmacy and  
20 Dentistry, University of Sciences Techniques and Technologies of Bamako; P.O  
21 Box 1805, Bamako, Mali.

22 <sup>5</sup>Laboratory of Malaria Immunology and Vaccinology, National Institute of  
23 Allergy and Infectious Diseases, National Institutes of Health. Bethesda, MD,  
24 USA

25 <sup>6</sup>Laboratório de Imunobiologia das Leishmanioses, Departamento de  
26 Imunologia, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro,  
27 Rio de Janeiro, Brazil;

28 <sup>7</sup>Laboratório de Alvos Moleculares, Departamento de Biotecnologia  
29 Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de  
30 Janeiro, Rio de Janeiro, Brazil;

31

32 **\*Corresponding authors' e-mails:**

33 heitorapneto@gmail.com (HAPN)

34 mbozza@micro.ufrj.br (MTB)

35

## 36 **Abstract**

37 Neutrophil extracellular traps (NETs) evolved as a unique effector mechanism  
38 contributing to resistance against infection that can also promote tissue damage  
39 in inflammatory conditions. Malaria infection can trigger NET release, but the  
40 mechanisms and consequences of NET formation in this context remain poorly  
41 characterized. Here we show, similarly to previous reports, that patients  
42 suffering from severe malaria had increased amounts of circulating DNA and  
43 increased neutrophil elastase (NE) levels in plasma. We used cultured  
44 erythrocytes and isolated human neutrophils to show that *Plasmodium*-infected  
45 red blood cells release MIF, which in turn caused NET formation by neutrophils  
46 in a mechanism dependent on the C-X-C chemokine receptor type 4 (CXCR4).  
47 NET production was dependent on histone citrullination by PAD4 and  
48 independent of reactive oxygen species (ROS), myeloperoxidase (MPO) or NE.  
49 In vitro, NETs functioned to restrain parasite dissemination in a mechanism  
50 dependent on MPO and NE activities. Finally, C57/B6 mice infected with *P.*  
51 *berghei* ANKA, a well-established model of cerebral malaria, presented high  
52 amounts of circulating DNA, while treatment with DNase increased parasitemia  
53 and accelerated mortality, indicating a role for NETs in resistance against  
54 *Plasmodium* infection.

55

## 56 **Author summary**

57 Protozoans of the *Plasmodium* genre infect red blood cells and cause malaria in  
58 humans and various other mammalian species. Estimated malaria cases are at  
59 more than 200 million, with 450,000 deaths per year, being cerebral malaria a  
60 serious complication that accounts for the majority of deaths. Neutrophils are

61 cells that participate in host defense against pathogens. These cells use various  
62 mechanisms to kill invading microorganisms, including the release of webs of  
63 DNA, called neutrophil extracellular traps (NETs). These NETs can help control  
64 infections but can also induce tissue damage and their role in malaria and the  
65 mechanisms of NET production during malaria infection are starting to be  
66 understood. Here we show that infected red blood cells produce a cytokine,  
67 macrophage migration inhibitory factor (MIF) that stimulates neutrophils to  
68 release NETs. These NETs function to limit *Plasmodium* dissemination and,  
69 thus, digestion of NETs with DNase treatment causes increased parasitemia  
70 and accelerated death in an experimental model of cerebral malaria. Our study  
71 uncovers the mechanism by which infected red blood cells stimulate neutrophils  
72 to release NETs and suggest an important participation of this process in  
73 malaria control.

## 74 **Introduction**

75 Malaria is a highly prevalent and widespread infectious disease caused by  
76 protozoans of the *Plasmodium* genus. Amongst the known agents of human  
77 malaria, *Plasmodium falciparum* is associated with the complicated forms of  
78 disease, including the potentially fatal cerebral malaria [1,2]. Severe forms of  
79 malaria infection can be associated with either impaired mechanisms of  
80 resistance - and consequently high parasitemia [3,4] - or exacerbated tissue  
81 damage due to ineffective mechanisms of disease tolerance [5-8]. Studies on  
82 the immunological mechanisms of tissue injury and host resistance to malarial  
83 infection have generally focused on adaptive immune responses coordinated by  
84 CD4+ T cells through the activation of CD8+ T and B cells [9-11]. However,  
85 mounting evidences, from both human studies and the *P. berghei* ANKA murine  
86 model of severe malaria, point to the involvement of other cell types, including  
87 platelets, macrophages and neutrophils [12-15].

88 Neutrophils participate in the immune response to pathogens by using several  
89 mechanisms of killing, including reactive oxygen species (ROS) production,  
90 phagocytosis, and the release of antimicrobial peptides and cytotoxic enzymes  
91 [16]. Neutrophils are capable of phagocytosing opsonized *P. falciparum*  
92 merozoites [17] and *P. falciparum*-infected red blood cells [18]. Neutrophil ROS  
93 production positively correlated with *P. falciparum* clearance and individuals  
94 with higher ROS production presented faster parasite clearance time (PCT)  
95 [19]. These observations would support a beneficial role of neutrophils in  
96 mediating *Plasmodium* clearance and disease resistance in malaria. However,  
97 in human malaria there is a strong correlation between neutrophil activation  
98 markers and disease severity [14, 20, 21], suggesting that overt neutrophil

99 activation may contribute to disease pathogenesis. In fact, neutrophil depletion  
100 resulted in decreased brain microhaemorrhages and monocyte sequestration,  
101 preventing cerebral malaria development in mice [22, 23]. Therefore, whether  
102 neutrophils are beneficial, contributing to pathogen clearance or detrimental,  
103 inducing tissue damage during severe malaria remains unresolved.

104 Neutrophils can release DNA to the extracellular space, which has been shown  
105 to function as traps for many different pathogens, including bacteria, fungi,  
106 viruses and protozoans. These neutrophil extracellular traps (NET) evolved as a  
107 unique innate immune defense mechanism capable of restraining pathogens,  
108 avoiding their dissemination and contributing to pathogen killing [24]. However,  
109 NETs have also the potential to harm surrounding healthy tissue, thus  
110 contributing to both aspects of disease tolerance, i.e. pathogen elimination and  
111 collateral tissue damage. It is therefore reasonable to hypothesize that  
112 neutrophils and NETs may be involved in malaria pathogenesis. In fact, reports  
113 show evidences of NET production in samples from human malaria patients [25,  
114 26]. Moreover, it was recently shown that *Plasmodium*-infected red blood cells  
115 are capable of triggering NET release [27]. NET disruption with DNase  
116 treatment resulted in milder lung injury and increased survival in a model of  
117 *Plasmodium*-induced acute lung injury [27]. However, the mechanisms involved  
118 in NET release in response to *Plasmodium*-infected erythrocytes remain  
119 uncharacterized.

120 In the present study, we show that NETs are released by neutrophils exposed  
121 to *Plasmodium*-infected erythrocytes and contribute to restrain pathogen spread  
122 and control malaria infection. We also provide evidences that stimulation of NET

- 123 release is independent of cell-cell contact and is mediated by macrophage  
124 migration inhibitory factor (MIF) activation of CXCR4.

## 125 **Results**

### 126 ***P. falciparum*-infected erythrocytes induce NETs.**

127 Evidences in both humans and mice suggest that malaria infection triggers NET  
128 release. We analyzed blood samples from patients with severe malaria (S.M.)  
129 or uncomplicated malaria (U.M.) for signs of NET. We observed that patients  
130 with S.M. showed increased circulating neutrophil elastase (NE) levels (Fig 1A)  
131 as well as increased circulating nucleosomes (Fig 1B), suggestive of NETs. To  
132 further evaluate the potential of *P. falciparum*-infected red blood cells (iRBCs) in  
133 inducing NET release, human peripheral blood neutrophils were incubated with  
134 infected erythrocytes at increasing neutrophil to iRBC ratios. After 3 h, a  
135 significant increase in extracellular DNA content could be detected in  
136 supernatant of neutrophils cultured in the presence of infected erythrocytes  
137 relative to unstimulated neutrophil controls (Fig 1C). Data representation as  
138 absolute extracellular DNA levels showed similar trends (S1A Fig). Increased  
139 extracellular DNA content was evident in a 1:1 ratio and was even more  
140 pronounced at a 5:1 ratio, reaching a 6- to 7-fold increase relative to control  
141 neutrophils (Fig 1C). Incubation of human neutrophils at a lower (0.5:1)  
142 erythrocyte:neutrophil ratio did not induce any significant increase in  
143 extracellular DNA signal, as well as the incubation with uninfected red blood  
144 cells of the same donor at any of the tested ratios.

145 NET production induced by infected erythrocytes could be observed at very  
146 early time-points, with significant increases being detected at 15 min (Fig 1D).  
147 NET production was still high at 60 min and increased further at 180 min (Fig  
148 1D). NET release was paralleled by an increase in lactate dehydrogenase  
149 (LDH) activity in culture supernatants (S1B Fig). This suggests that NET

150 production in response to infected erythrocytes is accompanied by cell death,  
151 although it is difficult to ascertain whether LDH is derived from NETosing  
152 neutrophils or rupturing erythrocytes. We further observed that NET induced by  
153 *P. falciparum*-infected erythrocytes showed a cloud-like morphology (Fig 1E).  
154 Although we detected a significant extracellular DNA signal using fluorimetric  
155 assay as early as 15 minutes, NET-like structures only started to be detectable  
156 by immunofluorescence at 60 minutes (data not shown) and peaked at 180  
157 minutes (Fig 1E). NETs stained positively for NE and myeloperoxidase (MPO),  
158 two characteristic enzymes found associated to DNA in NETs (Fig 1E). Finally,  
159 these NET-like structures, as well as the fluorimetric signal were lost after  
160 DNase incubation (Fig 1F and 1G), suggesting that the structures we are  
161 describing here meet the criteria to be classified as NETs. Altogether, these  
162 results demonstrate that *P. falciparum*-infected erythrocytes stimulate human  
163 neutrophils to release NETs *in vitro*.

#### 164 **Mechanisms underlying NET production induced by infected erythrocytes.**

165 *P. falciparum*-infected erythrocytes triggered a strong ROS production by  
166 human neutrophils (S2A Fig). However NET release in response to infected  
167 erythrocytes was not inhibited by neither DPI treatment (Fig 2A) nor NAC (S2B  
168 Fig), despite their capacity to block ROS production induced by infected  
169 erythrocytes (S2C and S2D Figs). These results suggest that NET release in  
170 response to infected red blood cells is ROS-independent. Moreover, we  
171 observed that uninfected erythrocytes were also able to induce ROS production  
172 by human neutrophils, although to a smaller extent (S2C and S2D Figs). This  
173 also argues against a possible involvement of ROS in NET release induced by  
174 infected erythrocytes since we did not observe any NET production in response



175 to uninfected red blood cells (Fig 1C). MPO and NE were reported to be  
176 essential to NET production induced by different stimuli [28, 29]. We used two  
177 well described inhibitors of MPO and NE to evaluate the involvement of these  
178 two enzymes in NET production induced by *P. falciparum*-infected erythrocytes.  
179 Neither inhibitor had any effects on NET production in this model, ruling out the  
180 involvement of MPO and NE in this process (Figs 2B and 2C).

181 Another important step in NET release is histone citrullination by PAD4 [30, 31].  
182 Incubation of human neutrophils with infected erythrocytes induced a strong  
183 increase in histone citrullination, as observed by both Western blot (Fig 2D) and  
184 immunofluorescence (S3 Fig). Treatment of neutrophils with the PAD4 inhibitor,  
185 Cl-amidine, resulted in significant inhibition of NET production (Fig 2E),  
186 suggesting the involvement of PAD4-induced histone citrullination in this  
187 process. We treated neutrophils with different kinase inhibitors to define the  
188 signaling pathways contributing to NET release in response to infected  
189 erythrocytes. Incubation of human neutrophils with *P. falciparum*-infected red  
190 blood cells induced increased PKC $\delta$  expression, in agreement with the  
191 observed increased ROS production. We also observed increased  
192 phosphorylation of Akt, JNK and p38 (S4A Fig). Inhibition of JNK  
193 phosphorylation with SP600125 significantly inhibited NET release (S4B Fig).  
194 On the other hand, inhibition of p38 did not have any effect (S4C Fig). Together,  
195 our results suggest that NET release by human neutrophils in response to *P.*  
196 *falciparum*-infected red blood cells is dependent on JNK and PAD4, but  
197 independent of ROS, NE, MPO and p38.

198 **NET production induced by infected erythrocytes does not depend on**  
199 **integrins or CD36.**

200 Integrins are expressed by neutrophils and mediate a series of their biological  
201 functions. Previous studies have implicated CD18/CD11b (Mac-1) in NET  
202 production by different stimuli, including *Candida albicans*  $\beta$ -glucan [32] and  
203 immobilized immune complexes [33]. We incubated neutrophils with a CD18  
204 blocking antibody during the interaction with infected erythrocytes. We found no  
205 effects of anti-CD18, or the isotype control antibody, on NET release induced by  
206 infected erythrocytes (Fig 3A). *P. falciparum*-infected erythrocytes interact with  
207 endothelial cells through *P. falciparum* erythrocyte membrane protein 1 (PfEMP-  
208 1) expressed by infected erythrocytes. PfEMP-1 mediates cytoadhesion of  
209 infected erythrocytes to endothelia through its interaction with CD36 and ICAM-  
210 1 expressed by endothelial cells [34, 35]. We reasoned that CD36 or ICAM-1  
211 could have a role in mediating the recognition of infected erythrocytes and NET  
212 production by human neutrophils. Incubation of neutrophils with an ICAM-1  
213 blocking antibody did not interfere with NET production induced by infected  
214 erythrocytes (Fig 3B). Similarly, incubation with an anti-CD36 blocking antibody  
215 did not inhibit NET release (Fig 3C). These results show that neither of the  
216 integrins known to be involved in NET production or erythrocyte cytoadherence,  
217 nor CD36 are involved in the stimulation of NET release by infected  
218 erythrocytes. We further treated neutrophils with cytochalasin D, a disruptor of  
219 actin polymerization that inhibits phagocytosis. There are evidences of  
220 neutrophil phagocytosis of infected red blood cells in human patients and also  
221 there are evidences that phagocytosis may inhibit NET release [36]. However,  
222 despite these evidences, NET release was neither increased nor decreased by  
223 cytochalasin D (Fig 3D), ruling out the involvement of phagocytosis in this  
224 process.

225 **NET production in response to infected RBCs is triggered by macrophage**  
226 **migration inhibitory factor (MIF).**

227 Recently it was demonstrated that aged neutrophils presenting increased  
228 CXCR4 expression show enhanced capacity of NET release [37]. Moreover, a  
229 report by Sercundes and cols. showed that NETs are involved in pulmonary  
230 injury in a murine model of malaria and that CXCR4 inhibition protected mice  
231 from acute lung injury [27]. We therefore used AMD3100, a CXCR4 antagonist,  
232 to evaluate the involvement of CXCR4 in this model. We observed that  
233 AMD3100 inhibited NET release induced by infected red blood cells (Fig 4A).  
234 CXCL12 is the typical CXCR4 ligand, but this receptor can also be activated by  
235 MIF, which functions as a non-cognate ligand [38]. Moreover, it has been  
236 demonstrated that red blood cells are an important source of MIF, contributing  
237 with ~99% of total MIF content in blood [39]. In fact, the cell-permeable MIF  
238 antagonist, ISO 1, was able to inhibit NET release in response to infected  
239 erythrocytes (Fig 4B). Additionally, treatment with an anti-MIF blocking antibody  
240 resulted in a significant inhibition of NET release induced by infected  
241 erythrocytes (Fig 4C). Finally, we could detect the presence of MIF in the  
242 supernatant of infected, but not uninfected, erythrocytes (Fig 4D). Supernatant  
243 derived from cultures of infected erythrocytes induced NET release by human  
244 neutrophils (Fig 4E), an effect that could be blocked by anti-MIF antibody (Fig  
245 4F). Altogether, these results indicate that MIF is a soluble mediator released by  
246 *P. falciparum*-infected erythrocytes that induce NET release by human  
247 neutrophils.

248 **NET restricts parasite dissemination and contributes to host survival.**

249 To test the biological significance of NET formation to malaria pathogenesis, we  
250 first treated *P. falciparum*-infected erythrocyte cultures with NET rich  
251 supernatant collected from human neutrophils previously stimulated with  
252 infected erythrocytes. Presence of NETs resulted in fewer ring structures and  
253 decreased proportions of infected erythrocytes in culture (Figs 5A and 5B,  
254 respectively). Accordingly, DNase treatment restored the percentage of ring  
255 structures to those found in untreated cultures (Fig 5C), suggesting that NETs  
256 interfere with *P. falciparum* dissemination *in vitro*. Additionally, treatment of  
257 cultures with either MPO or NE inhibitors also resulted in increased levels of  
258 ring structures compared to cultures in the presence of NET (Figs 5D and 5E,  
259 respectively). This suggests that, despite being dispensable to NET release,  
260 MPO and NE activity participate in NET-mediated control of parasite  
261 dissemination.

262 We then moved to a murine model of malaria, using *P. berghei* ANKA and bone  
263 marrow-derived neutrophils from C57/BL6 mice. *P. berghei* ANKA is known to  
264 induce a severe form of cerebral malaria in susceptible C57/BL6 mice and is  
265 generally used as a model for the human form of *P. falciparum*-induced cerebral  
266 malaria. Similarly to what we found in human neutrophils, incubation of mouse  
267 neutrophils with *P. berghei*-infected red blood cells induced a significant  
268 increase in extracellular DNA that was not observed in neutrophils incubated  
269 with uninfected erythrocytes (Fig 6A). NET release by murine neutrophils was  
270 also ROS-independent since it was unaffected by either DPI (Fig 6B) or NAC  
271 treatment (S5A Fig), despite the strong ROS production induced by infected red  
272 blood cells (S5B Fig). Morphologically, NETs from murine neutrophils also  
273 stained positively for MPO and citrullinated histones, but were slightly distinct

274 from NETs released by human neutrophils in that it showed a fiber-like structure  
275 (Fig 6C). Together, these results show that, similarly to what we described for  
276 human neutrophils in response to *P. falciparum*-infected erythrocytes, murine  
277 neutrophils release NET in response to *P. berghei* ANKA-infected erythrocytes,  
278 in a process that is independent of ROS.

279 Finally, infection of C57/BL6 mice with *P. berghei* ANKA resulted in increased  
280 plasmatic levels of circulating DNA (Fig 6D), which corroborates with our data  
281 from S.M. patients (Fig 1B). *P. berghei* ANKA infection also resulted in sharp  
282 mortality starting at day 7 and that reached a 40% survival rate by day 10 (Fig  
283 6E). Treatment of mice with DNase (Pulmozyme) resulted in accelerated death,  
284 with 20% survival at day 7 and 100% mortality by day 10 post-infection (Fig 6E).  
285 Interestingly, this DNase effect was paralleled by a significant increase in  
286 parasitemia (Fig 6F), suggesting that NET functions to restrain parasite  
287 dissemination *in vivo* in a similar fashion to what we observed *in vitro*.

## 288 Discussion

289 Herein we show that *Plasmodium*-infected red blood cells release MIF that  
290 induce NET formation by human and mouse neutrophils *in vitro*. Addition of  
291 purified NET to infected erythrocyte cultures reduced the proportion of parasite-  
292 positive cells in a mechanism dependent on MPO and NE. Since MPO and NE  
293 are cytotoxic, it is possible that in malaria infection NET serves not only as a  
294 trap, but also to kill free parasites. Patients suffering from severe malaria have  
295 increased amounts of circulating DNA, paralleled by increased NE levels in  
296 plasma. To gain insight into the contribution of NET to malaria pathophysiology,  
297 we used a well described mouse model of severe malaria caused by *P. berghei*  
298 ANKA. Infected mice had higher amount of circulating DNA and treatment with  
299 DNase increased parasitemia and accelerated mortality, supporting a role for  
300 NET in the resistance against malaria infection.

301 *In vitro*, NET release in response to *Plasmodium*-infected erythrocytes occurred  
302 early (starting within the first 15 minutes of stimulation), was dependent of  
303 histone citrullination by PAD4 and independent of ROS, MPO or NE. This  
304 resembles the processes described as non-lytic NET release, documented in  
305 response to *Candida albicans*, *Staphylococcus aureus* and *Escherichia coli* [32,  
306 40, 41]. On the other hand, we found that NET release was accompanied by  
307 significant increase in extracellular LDH activity, suggestive of cell death. This  
308 LDH activity could come from neutrophils producing NET, from lysis of  
309 erythrocytes or both.

310 We observed that MIF, acting through CXCR4, were required to NET release  
311 induced by infected red blood cells. Recent evidences suggest that red blood  
312 cells are a major source of MIF in the bloodstream [39]. The mechanism by

313 which MIF is released from infected erythrocytes is not well characterized. MIF  
314 might be released after red cell lysis during the parasite cycle. However, unless  
315 erythrocytes lyse immediately upon co-culture with neutrophils, only the  
316 continuous release of MIF would explain NET being triggered as soon as 15  
317 minutes. One possible alternative is that MIF could be released within red blood  
318 cell-derived microvesicles that are continuously shed by infected erythrocytes  
319 independently of parasite cycling [42]. Another possibility is that in response to  
320 infection, red blood cells are stimulated to continuously release MIF  
321 independent of microvesicles. A previous study reported that MIF potentiates  
322 *Pseudomonas aeruginosa*-induced NET release in both humans and murine  
323 neutrophils [43]. The mechanisms and signaling pathways triggered by the  
324 MIF/CXCR4 axis that contribute to NET release require further investigations.  
325 The protective role of NET described here contrasts with reports demonstrating  
326 the contribution of NETs to tissue damage upon experimental *Plasmodium*  
327 infection. DNase treatment of mice, or neutrophil depletion, alleviated lung  
328 injury and resulted in increased survival of mice in a model of malaria-  
329 associated acute lung injury [27]. Moreover, neutrophil depletion has been  
330 shown to be beneficial in different studies [12, 22, 23, 44]. Most of these  
331 studies, however, use different mouse strains and *Plasmodium* species, which  
332 may account for differences in outcome. Ioannidis and cols. used the same  
333 experimental model of *P. berghei* ANKA infection of cerebral malaria  
334 susceptible C57B6 mice [12]. In their study neutrophils played a detrimental role  
335 as a significant source of CXCL10, since neutrophil depletion or CXCL10  
336 ablation prevented C.M. development. These results can be reconciled when  
337 considering a double-edged role for neutrophils in malaria pathogenesis: NET

338 release could be beneficial, by limiting parasite dissemination, but overt  
339 neutrophil activation would result in tissue injury that overcomes any benefit.  
340 This can explain why depleting neutrophils results in increased survival while  
341 targeting NET alone (with DNase treatment) results in increased susceptibility  
342 in the mouse model of C.M. caused by *P. berghei* ANKA. Similar to our finding  
343 in malaria patients, a recent report showed evidences of NET formation in  
344 human patients suffering from complicated malaria which positively correlated  
345 with clinical manifestations [26]. It is possible that overt neutrophil activation is  
346 occurring in these patients, resulting in increased NET release but also  
347 increased NET-independent tissue injury, i.e. by increased proteolytic activity,  
348 cytokine release and/or increased oxidative stress. Therefore, attempts to target  
349 NET or neutrophils in malaria should be taken with caution and consider the  
350 complex interplay between both beneficial and detrimental roles played by  
351 neutrophils in malaria.



## 352 **Materials and methods**

### 353 **Human studies.**

354 Prior to enrollment, written informed consent was obtained from the  
355 parents/guardians on behalf of their children after receiving a study explanation  
356 form and oral explanation from a study clinician in their native language. The  
357 protocol and study procedures were approved by the institutional review board  
358 of the National Institute of Allergy and Infectious Diseases at the US National  
359 Institutes of Health (ClinicalTrials.gov ID NCT01168271), and the Ethics  
360 Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University  
361 of Bamako, Mali.

### 362 **Description of population and study site.**

363 Children aged 0-10 years of age were enrolled in the health district of  
364 Ouélessébougou. Ouélessébougou is located about 80 km south from Bamako,  
365 the capital city of Mali, and contains the district health center and a Clinical  
366 Research Center located in the community health center where studies of  
367 malaria and other infectious disease have been ongoing since 2008. The district  
368 covers 14 health sub-districts. In 2008, in the town of Ouélessébougou, the  
369 incidence rate of clinical malaria in under-5 year-olds was 1.99  
370 episodes/child/year and the incidence rate of severe malaria as defined by  
371 WHO criteria was about 1-2% in this age group during the transmission season.  
372 Malaria is the most frequent cause of admission in the pediatric service,  
373 representing 44.9% of admissions, followed by acute respiratory infections  
374 (26.4%) and diarrhea (11.2%) [45]. Malaria transmission is highly seasonal in  
375 the study area.

376 **Blood Collection.**

377 Samples were collected from 23 children with severe malaria (from the febrile  
378 hospitalization cohort) and 42 participants with mild malaria (from the  
379 longitudinal under-5 cohort, matched for age). Of the 23 severe malaria cases,  
380 8 had cerebral malaria while the remaining had severe anemia or prostration.  
381 Venous blood was drawn in EDTA tubes, and plasma was prepared by  
382 centrifuging for 10 min at 1500g. Plasma was aliquoted and stored at -80°C.

383 **ELISA.**

384 ELISA kits used were Neutrophil Elastase (Abcam 119553, plasma dilution  
385 1:500; standard range, 0.16-10 ng/ml) and Cell Death ELISA (Roche,  
386 11774425001, plasma dilution 1:2) which estimates cytoplasmic histone-  
387 associated DNA fragments (mono- and oligonucleosomes, no standard range).  
388 For the ordinal variables, differences between groups were calculated using the  
389 non-parametric Mann-Whitney test.

390 **Neutrophil purification.**

391 Human neutrophils were isolated from peripheral blood using a histopaque  
392 1077 density gradient as previously described [46]. Erythrocytes were lysed  
393 with ACK solution and the pellet containing neutrophils was washed in HBSS  
394 and resuspended in cold RPMI 1640 medium. Isolated neutrophils were  
395 routinely  $\geq 95\%$  pure and  $>99\%$  viable. Murine neutrophils were isolated from  
396 the bone marrow of C57/BL6 mice by percoll density gradient as described [47].  
397 Isolated neutrophils were resuspended in cold RPMI 1640 medium. Purity was  
398 routinely  $\geq 95\%$  pure and viability  $>99\%$ .

399 **Neutrophil treatment.**

400 To evaluate the participation of ROS in NET production, neutrophils were pre-  
401 treated with diphenyleneiodonium chloride (DPI, Sigma-Aldrich, 10 µg/mL) or N-  
402 Acetyl-L-cysteine (NAC, Sigma-Aldrich, 10 µM). Neutrophils were pretreated  
403 with pharmacological inhibitors to MPO (MPOi, Santa Cruz Biotechnology, 10  
404 µg/mL), neutrophil elastase (NEi, Santa Cruz Biotechnology, 10 µg/mL), PDA4  
405 (Cl-amidine, Cayman Chemical , 12 µM), CXCR4 (AMD3100, Sigma-Aldrich,  
406 100 ng/ml), MIF (ISO-1, Abcam, 50µM), JNK (SP600125, Sigma-Aldrich, 40  
407 µM), p38 MAPK (SB239063, Sigma-Aldrich, 20 µM), and phagocytosis  
408 (cytochalasin-D, Sigma-Aldrich , 8 µM). Finally, neutrophils were also treated  
409 with blocking antibodies to MIF (kindly provided by Dr. R. Bucala, 20µg/ml),  
410 CD18 (20µg/ml, Abcam), CD36 (20µg/ml, Abcam) or ICAM-1(20µg/ml; R&D  
411 Systems), or the appropriate isotype control IgG (20 µg/ml, Abcam). All  
412 inhibitors and antibodies were added to neutrophil cultures 30 minutes before  
413 stimulation.

414 **Parasite cultures.**

415 *Plasmodium falciparum* W2 strain was cultured in human A+ type erythrocytes  
416 at 37°C under controlled gas atmosphere (5% CO<sub>2</sub>, 5% O<sub>2</sub>, 90% N<sub>2</sub>), in RPMI  
417 supplemented with 20 mM HEPES, 22 mM glucose, 0.3 mM hypoxanthine, 0.5  
418 % albumax II and 20 µg/mL of gentamycin [48]. Culture parasitemia was  
419 determined daily through thick blood smear stained with Diff-Quick and  
420 maintained around 2% at a 4 to 5% hematocrit. Parasitemia (number of infected  
421 RBC per 100 RBCs) was determined by counting at least 500 cells. In a  
422 selected experiment, supernatant from infected cultures was collected and

423 immediately added to neutrophil cultures. Supernatant from uninfected  
424 erythrocytes was used as control.

#### 425 **Mature trophozoites purification.**

426 Mature trophozoites were isolated by percoll/sorbitol gradient as described  
427 previously [49]. Briefly, cultures of infected erythrocytes with at least 5%  
428 parasitemia were centrifuged at 900g for 15 min at room temperature. Pellet  
429 was resuspended in fresh RPMI to reach a 20% hematocrit and gently poured  
430 on top of a 40%, 70% and 90% Percoll/sorbitol gradient. After centrifugation the  
431 brown band formed between the 40% and 70% layers was harvested and  
432 suspensions of synchronized trophozoites (>90% of purity) were used to  
433 stimulate neutrophils.

#### 434 **Fluorimetric quantification of NETs.**

435 Neutrophils ( $2 \times 10^5$  cells) were stimulated with *P. falciparum*-infected  
436 erythrocytes at varying neutrophil:erythrocyte ratios. After incubation, ECOR1  
437 and HIINDIII restriction enzymes (20 units/mL each) were added and incubated  
438 for 30 min at 37°C. Samples were then centrifuged and supernatants collected.  
439 DNA concentration in the supernatants (referred to as NETs) was determined  
440 using Picogreen dsDNA kit (Invitrogen) according to the manufacturer's  
441 instructions. Uninfected erythrocytes from the same blood type were used as  
442 control.

#### 443 **Visualization of NETs by immunofluorescence.**

444 Neutrophils ( $2 \times 10^5$ ) were allowed to adhere onto 0.001% poly-L-lysine (Sigma)  
445 coated glass coverslips. Neutrophil were then stimulated with  $1 \times 10^6$  *P.*

446 *falciparum*-infected erythrocytes for 3 h. Cells were fixed with 4%  
447 paraformaldehyde for 15 min at room temperature. After extensive wash in  
448 PBS, unspecific binding sites were blocked with 3% BSA and cells were  
449 incubated with primary anti-myeloperoxidase (1:1000, Abcam), anti-elastase  
450 (1:1000, Abcam), or anti-citrullinated histone H3 (1:1000, Abcam) antibodies,  
451 followed by the appropriate secondary fluorescent antibodies (1:4000). DNA  
452 was counterstained with Hoesch. Images were acquired using a Leica confocal  
453 microscope under 40X and 100X magnification.

#### 454 **Quantification of ROS production.**

455 ROS production was measured using a fluorimetric assay based on the  
456 oxidation of the CM-H2DCFDA probe (Molecular Probes) following the  
457 manufacturer's instructions. Briefly,  $2 \times 10^5$  neutrophils and  $10^6$  infected  
458 erythrocytes were mixed with 2  $\mu$ M of CM-H2DCFDA probe in a 96 well plate.  
459 Fluorescence was monitored every 10 min for 30 min. Uninfected erythrocytes  
460 were used as controls. The same culture and stimulation procedure was carried  
461 out for the visualization of ROS production under the microscope. Images were  
462 acquired using a Leica DMI6000 fluorescence microscope under 20x  
463 magnification after 1 hour of stimulation.

#### 464 **Parasite invasion and growth assays.**

465 NET-rich supernatant was obtained from human neutrophils cultured with *P.*  
466 *falciparum*-infected erythrocytes at a 1:10 ratio for 3 hours. Cultures were  
467 centrifuged and NET-rich supernatant was collected for immediate use.  
468 Supernatant obtained from neutrophils incubated with uninfected red blood cells  
469 was used as control. Infected erythrocytes at 2% parasitemia were seeded in a

470 96-well plate in RPMI supplemented with 10% FCS to reach a 5% hematocrit.  
471 NET-rich supernatants were added to the erythrocyte cultures which were  
472 incubated at 37°C for 24 h. Parasite invasion was estimated by counting the  
473 number of new intracellular ring forms in a thick blood smear stained with Diff-  
474 Quick. Invasion was expressed as the percentage of erythrocytes showing ring  
475 forms of the parasite. Additionally, cultures were allowed to proceed for up to 48  
476 h to analyze intracellular parasite growth. The number of infected erythrocytes,  
477 including all parasite forms, was determined and expressed as the percentage  
478 of infected red blood cells (iRBC).

#### 479 **Westernblot.**

480 Whole-cell lysates were extracted by RIPA buffer and cleared by centrifugation  
481 at 15000xg for 15 min at 4°C prior to boiling in Laemmli buffer. Western blots  
482 were performed using standard molecular biology techniques and membranes  
483 were developed using Super Signal West Femto Maximum Sensitivity Substrate  
484 (Thermo Scientific). Blot images were acquired in a ChemiDoc XRS system  
485 (BioRad). Antibodies used were anti-p-JNK (Cell Signaling Technologies), anti-  
486 p-p38 (BD Biosciences), anti-p AKT (Cell Signaling Technologies), and anti-β-  
487 actin (Millipore). All primary antibodies were diluted 1:1000 in TBS-T.

#### 488 **In vivo assays.**

489 All animal procedures were approved by the Institution Ethics Committee  
490 (CEUA protocol number XXX). C57BL6 mice were treated intravenously with  
491 either vehicle (0.9% NaCl sterile saline) or Pulmozyme (5 mg/kg, Roche) 1 hour  
492 before infection. Pulmozyme treatment was continued every 8 hours for 6 days.  
493 Mice were infected with  $1 \times 10^5$  *P. berghei* ANKA. Mice were monitored daily for

494 clinical signs of cerebral malaria and blood samples were collected daily for  
495 parasitemia determination.

496 **Statistical analysis.**

497 Data are presented as means  $\pm$  S.E.M. of at least 3 independent experiments.  
498 All statistical analyses were performed using GraphPad Prism 6.0 for windows.  
499 One-way ANOVA was used for comparisons among multiple groups. Survival  
500 analysis was carried out using the built-in Prism survival analysis. Paired  
501 Student t-test was used to compare differences between cultures in the  
502 presence and absence of NET-rich supernatant. Differences with  $P < 0.05$  were  
503 considered as statistically significant.

## 504 **Acknowledgements**

505 The authors thank Prof. Richard Bucala and Dr. Lin Leng (Yale School of  
506 Medicine) for providing anti-MIF neutralizing monoclonal antibody ascite, and  
507 members of the Bozza Lab for helpful discussions. This work was financially  
508 supported by Conselho Nacional de Pesquisa (CNPq), Coordenação de  
509 Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de  
510 Amparo à Pesquisa do Rio de Janeiro (FAPERJ).



## 511 **References**

- 512 1. Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis  
513 WC, Wells TNC. Malaria. *Nat Rev Dis Primers*. 2017; 3: 17050.
- 514 2. de Koning-Ward TF, Dixon MW, Tilley L, Gilson PR. Plasmodium species:  
515 master renovators of their host cells. *Nat Rev Microbiol*. 2016; 14: 494-507.
- 516 3. Imwong M, Woodrow CJ, Hendriksen IC, Veenemans J, Verhoef H, Faiz MA,  
517 et al. Plasma concentration of parasite DNA as a measure of disease severity in  
518 falciparum malaria. *J Infect Dis*. 2015; 211: 1128-1133.
- 519 4. Kingston HW, Ghose A, Plewes K, Ishioka H, Leopold SJ, Maude RJ, et al.  
520 Disease Severity and Effective Parasite Multiplication Rate in Falciparum  
521 Malaria. *Open Forum Infect Dis*. 2017; 4: ofx169.
- 522 5. Gozzelino R, Andrade BB, Larsen R, Luz NF, Vanoaica L, Seixas E, et al.  
523 Metabolic adaptation to tissue iron overload confers tolerance to malaria. *Cell*  
524 *Host Microbe*. 2012; 12: 693-704.
- 525 6. Cumnock K, Gupta AS, Lissner M, Chevee V, Davis NM, Schneider DS.  
526 Host Energy Source Is Important for Disease Tolerance to Malaria. *Curr Biol*.  
527 2018; 28: 1635-1642.
- 528 7. Wang A, Huen SC, Luan HH, Baker K, Rinder H, Booth CJ, et al. Glucose  
529 metabolism mediates disease tolerance in cerebral malaria. *Proc Natl Acad Sci*  
530 *U S A*. 2018; 115: 11042-11047.
- 531 8. Ramos S, Carlos AR, Sundaram B, Jeney V, Ribeiro A, Gozzelino R, et al.  
532 Renal control of disease tolerance to malaria. *Proc Natl Acad Sci U S A*. 2019;  
533 116: 5681-5686.
- 534 9. Claser C, Malleret B, Gun SY, Wong AY, Chang ZW, Teo P, et al. CD8+ T  
535 cells and IFN- $\gamma$  mediate the time-dependent accumulation of infected red blood

- 536 cells in deep organs during experimental cerebral malaria. PLoS One. 2011; 6:  
537 e18720.
- 538 10. Villegas-Mendez A, Greig R, Shaw TN, de Souza JB, Gwyer Findlay E,  
539 Stumhofer JS, et al. IFN- $\gamma$ -producing CD4<sup>+</sup> T cells promote experimental  
540 cerebral malaria by modulating CD8<sup>+</sup> T cell accumulation within the brain. J  
541 Immunol. 2012; 189: 968-979.
- 542 11. de Oliveira RB, Wang JP, Ram S, Gazzinelli RT, Finberg RW, Golenbock  
543 DT. Increased survival in B-cell-deficient mice during experimental cerebral  
544 malaria suggests a role for circulating immune complexes. MBio. 2014; 5:  
545 e00949-14.
- 546 12. Ioannidis LJ, Nie CQ, Ly A, Ryg-Cornejo V, Chiu CY, Hansen DS.  
547 Monocyte- and Neutrophil-Derived CXCL10 Impairs Efficient Control of Blood-  
548 Stage Malaria Infection and Promotes Severe Disease. J Immunol. 2016; 196:  
549 1227-1238.
- 550 13. Schumak B, Klocke K, Kuepper JM, Biswas A, Djie-Maletz A, Limmer A, et  
551 al. Specific depletion of Ly6C(hi) inflammatory monocytes prevents  
552 immunopathology in experimental cerebral malaria. PLoS One. 2015; 10:  
553 e0124080.
- 554 14. Feintuch CM, Saidi A, Seydel K, Chen G, Goldman-Yassen A, Mita-  
555 Mendoza NK, et al. Activated Neutrophils Are Associated with Pediatric  
556 Cerebral Malaria Vasculopathy in Malawian Children. MBio. 2016; 7: e01300-  
557 15.
- 558 15. Pais TF, Chatterjee S. Brain macrophage activation in murine cerebral  
559 malaria precedes accumulation of leukocytes and CD8<sup>+</sup> T cell proliferation. J  
560 Neuroimmunol. 2005; 163: 73-83.

- 561 16. Ley K, Hoffman HM, Kubes P, Cassatella MA, Zychlinsky A, Hedrick CC, et  
562 al. Neutrophils: New insights and open questions. *Sci Immunol.* 2018; 3:  
563 eaat4579.
- 564 17. Kumaratilake LM, Ferrante A. Opsonization and phagocytosis of  
565 *Plasmodium falciparum* merozoites measured by flow cytometry. *Clin Diagn Lab*  
566 *Immunol.* 2000; 7: 9-13.
- 567 18. Celada A, Cruchaud A, Perrin LH. Phagocytosis of *Plasmodium falciparum*-  
568 parasitized erythrocytes by human polymorphonuclear leukocytes. *J Parasitol.*  
569 1983; 69: 49-53.
- 570 19. Greve B, Lehman LG, Lell B, Luckner D, Schmidt-Ott R, Kremsner PG.  
571 High oxygen radical production is associated with fast parasite clearance in  
572 children with *Plasmodium falciparum* malaria. *J Infect Dis.* 1999; 179: 1584-  
573 1586.
- 574 20. Otterdal K, Berg A, Michelsen AE, Patel S, Tellevik MG, Haanshuus CG, et  
575 al. Soluble markers of neutrophil, T-cell and monocyte activation are associated  
576 with disease severity and parasitemia in *falciparum* malaria. *BMC Infect Dis.*  
577 2018; 18: 670.
- 578 21. Knackstedt SL, Georgiadou A, Apel F, Abu-Abed U, Moxon CA, Cunnington  
579 AJ, et al. Neutrophil extracellular traps drive inflammatory pathogenesis in  
580 malaria. *Sci Immunol.* 2019; 4. pii: eaaw0336.
- 581 22. Chen L, Zhang Z, Sendo F. Neutrophils play a critical role in the  
582 pathogenesis of experimental cerebral malaria. *Clin Exp Immunol.* 2000; 120:  
583 125-33.
- 584 23. Porcherie A, Mathieu C, Peronet R, Schneider E, Claver J, Commere PH, et  
585 al. Critical role of the neutrophil-associated high-affinity receptor for IgE in the

- 586 pathogenesis of experimental cerebral malaria. *J Exp Med.* 2011; 208: 2225-  
587 2236.
- 588 24. Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and  
589 chronic inflammation. *Blood.* 2019; 133: 2178-2185.
- 590 25. Baker VS, Imade GE, Molta NB, Tawde P, Pam SD, Obadofin MO, et al.  
591 Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in  
592 *Plasmodium falciparum* infected children under six years of age. *Malar J.* 2008;  
593 7: 41.
- 594 26. Kho S, Minigo G, Andries B, Leonardo L, Prayoga P, Poespoprodjo JR, et  
595 al. Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are  
596 Increased in Proportion to Disease Severity in Human Malaria. *J Infect Dis.*  
597 2019; 219: 1994-2004.
- 598 27. Sercundes MK, Ortolan LS, Debone D, Soeiro-Pereira PV, Gomes E, Aitken  
599 EH, et al. Targeting Neutrophils to Prevent Malaria-Associated Acute Lung  
600 Injury/Acute Respiratory Distress Syndrome in Mice. *PLoS Pathog.* 2016; 12:  
601 e1006054.
- 602 28. Metzler KD, Fuchs TA, Nauseef WM, Reumaux D, Roesler J, Schulze I, et  
603 al. Myeloperoxidase is required for neutrophil extracellular trap formation:  
604 implications for innate immunity. *Blood.* 2011; 117: 953-959.
- 605 29. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil  
606 elastase and myeloperoxidase regulate the formation of neutrophil extracellular  
607 traps. *J Cell Biol.* 2010; 191: 677-691.
- 608 30. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone  
609 hypercitrullination mediates chromatin decondensation and neutrophil  
610 extracellular trap formation. *J Cell Biol.* 2009; 184: 205-213.

- 611 31. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential  
612 for antibacterial innate immunity mediated by neutrophil extracellular traps. *J*  
613 *Exp Med.* 2010; 207: 1853-1862.
- 614 32. Byrd AS, O'Brien XM, Johnson CM, Lavigne LM, Reichner JS. An  
615 extracellular matrix-based mechanism of rapid neutrophil extracellular trap  
616 formation in response to *Candida albicans*. *J Immunol.* 2013; 190: 4136-4148.
- 617 33. Behnen M, Leschczyk C, Möller S, Batel T, Klinger M, Solbach W, et al.  
618 Immobilized immune complexes induce neutrophil extracellular trap release by  
619 human neutrophil granulocytes via FcγRIIIB and Mac-1. *J Immunol.* 2014; 193:  
620 1954-1965.
- 621 34. McCormick CJ, Craig A, Roberts D, Newbold CI, Berendt AR. Intercellular  
622 adhesion molecule-1 and CD36 synergize to mediate adherence of  
623 *Plasmodium falciparum*-infected erythrocytes to cultured human microvascular  
624 endothelial cells. *J Clin Invest.* 1997; 100: 2521-2529.
- 625 35. Baruch DI, Gormely JA, Ma C, Howard RJ, Pasloske BL. *Plasmodium*  
626 *falciparum* erythrocyte membrane protein 1 is a parasitized erythrocyte receptor  
627 for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.  
628 *Proc Natl Acad Sci U S A.* 1996; 93: 3497-3502.
- 629 36. Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, Brown GD,  
630 et al. Neutrophils sense microbe size and selectively release neutrophil  
631 extracellular traps in response to large pathogens. *Nat Immunol.* 2014; 15:  
632 1017-1025.
- 633 37. Zhang D, Chen G, Manwani D, Mortha A, Xu C, Faith JJ, et al. Neutrophil  
634 ageing is regulated by the microbiome. *Nature.* 2015; 525: 528-532.

- 635 38. Bernhagen J, Krohn R, Lue H, Gregory JL, Zerneck A, Koenen RR, et al.  
636 MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and  
637 atherogenic cell recruitment. *Nat Med.* 13: 2007; 587-596.
- 638 39. Karsten E, Hill CJ, Herbert BR. Red blood cells: The primary reservoir of  
639 macrophage migration inhibitory factor in whole blood. *Cytokine.* 2018; 102: 34-  
640 40.
- 641 40. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, Zbytniuk LD, et al.  
642 Infection-induced NETosis is a dynamic process involving neutrophil  
643 multitasking in vivo. *Nat Med.* 2012; 18: 1386-1393.
- 644 41. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et al. A  
645 novel mechanism of rapid nuclear neutrophil extracellular trap formation in  
646 response to *Staphylococcus aureus*. *J Immunol.* 2010; 185: 7413-7425.
- 647 42. Mantel PY, Hoang AN, Goldowitz I, Potashnikova D, Hamza B, Vorobjev I,  
648 et al. Malaria-infected erythrocyte-derived microvesicles mediate cellular  
649 communication within the parasite population and with the host immune system.  
650 *Cell Host Microbe.* 2013; 13: 521-534.
- 651 43. Dwyer M, Shan Q, D'Ortona S, Maurer R, Mitchell R, Olesen H, et al. Cystic  
652 fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular  
653 trap release is regulated by macrophage migration-inhibitory factor. *J Innate*  
654 *Immun.* 2014; 6: 765-779.
- 655 44. Dey S, Bindu S, Goyal M, Pal C, Alam A, Iqbal MS, et al. Impact of  
656 intravascular hemolysis in malaria on liver dysfunction: involvement of hepatic  
657 free heme overload, NF- $\kappa$ B activation, and neutrophil infiltration. *J Biol Chem.*  
658 2012; 287: 26630-26646.

- 659 45. Sidibe T, Sangho H, Traore MS, Cissé MB, Togo B, Sy O, et al. Morbidity  
660 and mortality in the pediatric service at Gabriel Toure's University Hospital in  
661 Mali. *Mali Med.* 2008; 23: 34-37.
- 662 46. Guimarães-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado  
663 FN, Conceição-Silva F, et al. *Leishmania amazonensis* promastigotes induce  
664 and are killed by neutrophil extracellular traps. *Proc Natl Acad Sci U S A.* 2009;  
665 106: 6748-6753.
- 666 47. Boxio R, Bossenmeyer-Pourié C, Steinckwich N, Dournon C, Nüsse O.  
667 Mouse bone marrow contains large numbers of functionally competent  
668 neutrophils. *J Leukoc Biol.* 2004; 75: 604-611.
- 669 48. Trager W, Jensen JB. Human malaria parasites in continuous culture.  
670 *Science.* 1976; 193: 673-675.
- 671 49. Ribacke U, Moll K, Albrecht L, Ahmed Ismail H, Normark J, Flaberg E, et al.  
672 Improved in vitro culture of *Plasmodium falciparum* permits establishment of  
673 clinical isolates with preserved multiplication, invasion and rosetting  
674 phenotypes. *PLoS One.* 2013; 8: e69781.


675 **Figures**

676

677 **Fig 1**

678

Rodriguez et al. – Figure 01




679



680 **Fig 2**  
681  
682


Rodrigues et al. – Figure 02



683

684 **Fig 3**  
685


Rodrigues et al. – Figure 03



686

687 **Fig 4**


Rodrigues et al. – Figure 04



688

689 **Fig 5**


Rodrigues et al. – Figure 05



690

691 **Fig 6**

Rodrigues et al. – Figure 06



692

693 **Fig 1. *P. falciparum*-infected erythrocytes induce NETs.** (A) Neutrophil  
694 elastase and circulating nucleosomes (B) in plasma from human patients  
695 diagnosed with uncomplicated malaria (U.M., n=42) or severe malaria (S.M.,  
696 n=23). Mann-Whitney was performed for statistical significance between  
697 groups. P values are indicated in each graph. (C) Fluorimetric determination of  
698 NET production by human neutrophils in the presence of *P. falciparum*-infected  
699 red blood cells (iRBC) or uninfected RBC (cRBC) at varying red blood  
700 cell:neutrophil ratios. (D) Fluorimetric determination of NET production by  
701 human neutrophils in the presence of *P. falciparum*-infected red blood cells  
702 (iRBC) or uninfected RBC (cRBC) at different time-points. Data in C and D are  
703 presented as means  $\pm$  S.E.M. of the fold induction of extracellular DNA signal  
704 relative to resting neutrophils. (E) Visualization by fluorescence microscopy of  
705 NETs produced by human neutrophils in the presence of *P. falciparum*-infected  
706 (iRBC) or uninfected (cRBC) red blood cells for 3 hours. DNA is stained in blue  
707 (Hoesch), neutrophil elastase is stained in green (elastase) and  
708 myeloperoxidase is stained in red (MPO). Unstimulated human neutrophils were  
709 used as controls. (F) Representative images of the effect of DNase treatment  
710 on NET signal as visualized by fluorescence microscopy. Human neutrophils  
711 were incubated with iRBC or cRBC for 3 hours in the presence of DNase. DNA  
712 was stained with Hoesch. (G) Quantification of data derived from (F). Data are  
713 presented as means  $\pm$  S.E.M. of the fold induction of extracellular DNA signal  
714 relative to resting neutrophils. \*  $P < 0.05$  and \*\*\*  $P < 0.001$  relative to controls  
715 incubated with cRBC, #  $P < 0.01$  relative to untreated control.  
716

717 **Fig 2. Involvement of ROS, MPO, NE and PAD4 on NET production in**  
718 **response to infected erythrocytes.** Human neutrophils were treated with DPI  
719 (10 µg/mL) (A), MPO inhibitor (MPOi, 10 µg/mL) (B), neutrophil elastase  
720 inhibitor (NEi, 10 µg/mL) (C) or Cl-amidine (12 µM) (E) for 30 minutes and then  
721 incubated with *P. falciparum*-infected red blood cells (iRBC) for 3 hours. NET  
722 production was determined by fluorimetry. Uninfected red blood cells (cRBC)  
723 were used as control. Data are presented as means ± S.E.M. of the fold  
724 induction of extracellular DNA signal relative to resting neutrophils. (D)  
725 Representative westernblot image of citrullinated histone H3 in extracts of  
726 human neutrophils incubated for 3 hours in the presence of infected (iRBC) or  
727 uninfected (cRBC) red blood cells. β-actin was used as loading control. \* P<  
728 0.05 relative to controls incubated with cRBC, # P< 0.01 relative to untreated  
729 control.

730

731 **Fig 3. Involvement of CD18, ICAM-1, CD36 and phagocytosis on NET**  
732 **production in response to infected erythrocytes.** Human neutrophils were  
733 treated with neutralizing antibodies to CD18 (20µg/mL) (A), ICAM-1 (20µg/mL)  
734 (B) or CD36 (20µg/mL) (C) for 30 minutes and then incubated with *P.*  
735 *falciparum*-infected red blood cells (iRBC) at a 1:5 ratio for 3 hours. (D) Human  
736 neutrophils were treated with cytochalasin D (8 µM) for 30 minutes and then  
737 incubated with *P. falciparum*-infected red blood cells (iRBC) at a 1:5 ratio for 3  
738 hours. NET production was determined by fluorimetry. Uninfected red blood  
739 cells (cRBC) were used as control. Data are presented as means ± S.E.M. of  
740 the fold induction of extracellular DNA signal relative to resting neutrophils. \* P<  
741 0.05 relative to controls incubated with cRBC.

742

743 **Fig 4. Involvement of CXCR4-MIF axis on NET production in response to**  
744 **infected RBC.** Human neutrophils were treated with AMD3100 (AMD, 100  
745 ng/ml) (A), ISO-1 (ISO, 50 $\mu$ M) (B) or a neutralizing anti-MIF antibody ( $\alpha$ -MIF,  
746 20 $\mu$ g/mL) (C) for 30 minutes and then incubated with *P. falciparum*-infected red  
747 blood cells (iRBC) at a 1:5 ratio for 3 hours. NET production was determined by  
748 fluorimetry. Uninfected red blood cells (cRBC) were used as control. Data are  
749 presented as means  $\pm$  S.E.M. of the fold induction of extracellular DNA signal  
750 relative to resting neutrophils. (D) Quantification of MIF levels on supernatants  
751 from *P. falciparum*-infected (iRBCsn) or uninfected (cRBCsn) red blood cells.  
752 (E) Human neutrophils were incubated with supernatants from *P. falciparum*-  
753 infected (iRBCsn) or uninfected (cRBCsn) red blood cells and NET production  
754 was determined by fluorimetry. (F) Human neutrophils were treated with  
755 neutralizing anti-MIF ( $\alpha$ -MIF, 20 $\mu$ g/mL) or the appropriate isotype control (IgG)  
756 antibody and then incubated with supernatant from *P. falciparum*-infected  
757 (iRBCsn) or uninfected red blood cells (cRBCsn). NET production was  
758 determined by fluorimetry. Data are presented as means  $\pm$  S.E.M. of the fold  
759 induction of extracellular DNA signal relative to resting neutrophils. \*  $P < 0.05$   
760 relative to controls incubated with cRBC, #  $P < 0.01$  relative to untreated control.

761

762 **Fig 5. Effect of NETs on *P. falciparum* dissemination in cultures of human**  
763 **erythrocytes.** NET-rich supernatants were added to cultures of *P. falciparum*-  
764 infected erythrocytes and the proportion of erythrocytes presenting intracellular  
765 ring structures (A) or the proportion of infected erythrocytes (B) were  
766 determined after 48 hours. Supernatants from unstimulated neutrophils were



767 used as control. NET-rich supernatants were treated with DNase (C), MPO  
768 inhibitor (MPOi, 10 µg/mL) (D) or NE inhibitor (NEi, 10 µg/mL) (E) 30 minutes  
769 before adding to erythrocyte cultures and the proportion of erythrocytes  
770 presenting ring structures was determined after 48 hours as in A. \*\*\* P< 0.001  
771 relative to controls.

772

773 **Fig 6. *P. berguei* ANKA-infected erythrocytes induce NETs.** (A) Fluorimetric  
774 determination of NET production by murine neutrophils in the presence of *P.*  
775 *berguei* ANKA-infected mouse red blood cells (iRBC *Pb*ANKA) or uninfected  
776 RBC (cRBC) at varying red blood cell:neutrophil ratios. (B) Mouse neutrophils  
777 were pre-treated for 30 minutes with DPI and then incubated with *Pb*ANKA-  
778 infected RBC. NET production was determined by fluorimetry as before. Data in  
779 A and B are presented as means ± S.E.M. of the fold induction of extracellular  
780 DNA signal relative to resting neutrophils. (C) Visualization by fluorescence  
781 microscopy of NETs produced by murine neutrophils in the presence of  
782 *Pb*ANKA-infected (iRBC) or uninfected (cRBC) red blood cells. DNA is stained  
783 in blue (Hoesch), myeloperoxidase is stained in green (MPO) and citrullinated  
784 histone H3 (H3C) is stained in red. Unstimulated human neutrophils were used  
785 as controls. (D) Determination of circulating levels of DNA in plasma of *P.*  
786 *berguei* ANKA-infected C57BL6 mice 6 days after infection. (E) Mice were  
787 treated with DNase (Pulmozyme, 5 mg/kg i.p., 1 hour before and every 8 hours  
788 for 6 days) and survival after *Pb*ANKA infection was monitored for 21 days. (F)  
789 Parasitemia of mice treated with DNase (as in E) or vehicle and infected with  
790 *Pb*ANKA was monitored daily for 7 days. Data are presented as means ±

791 S.E.M. of the percentage of infected red blood cells. \*  $P < 0.05$  and \*\*  $P < 0.01$


792 relative to untreated controls.

793

794 **Supporting information**

795

Rodrigues et al. – Suppl. Figure 01



796


797

798 **S1 Fig.** (A) Fluorimetric determination of NET production by human neutrophils  
799 in the presence of *P. falciparum*-infected red blood cells (iRBC) or uninfected  
800 RBC (cRBC) at varying red blood cell:neutrophil ratios and represented as  
801 means  $\pm$  S.E.M. of the extracellular DNA fluorescence signal (in arbitrary units).  
802 (B) Determination of lactate dehydrogenase (LDH) activity in culture  
803 supernatants of human neutrophils incubated with infected red blood cells  
804 (iRBC) at two different neutrophil:red blood cell ratios for 3 hours. Uninfected  
805 red blood cells (cRBC) were used as controls. LDH activity in culture  
806 supernatants was compared to the total intracellular LDH activity as determined  
807 in neutrophil cell lysates. \*  $P < 0.05$  and \*\*\*  $P < 0.001$  relative to unstimulated  
808 neutrophils.

809

810

Rodrigues et al. – Suppl. Figure 02



811

812 **S2 Fig.** (A) Representative fluorescence images of ROS production by human

813 neutrophils incubated with infected (iRBC) or uninfected red blood cells (RBC)

814 at a 1:5 ratio in the presence of the ROS-sensitive CM-H2DCFDA probe. (B)

815 Human neutrophils were treated with NAC (10  $\mu$ M) for 30 minutes and then

816 incubated with *P. falciparum*-infected red blood cells (iRBC). NET production


817 was determined by fluorimetry. Uninfected red blood cells (cRBC) were used as

818 control. Data are presented as means  $\pm$  S.E.M. of the fold induction of  
819 extracellular DNA signal relative to resting neutrophils. (C and D) Kinetics of  
820 ROS production by human neutrophils incubated with infected red blood cells  
821 (iRBC) and treated or not with antioxidants DPI (C) or NAC (D). ROS production  
822 was evaluated by fluorimetry every 10 minutes for 30 minutes in the presence of  
823 CM-H2DCFDA.

824

825

Rodrigues et al. – Suppl. Figure 03




826

827

828 **S3 Fig.** Representative immunofluorescence images of human neutrophils  
829 incubated with *P. falciparum*-infected (iRBC) or uninfected (cRBC) red blood  
830 cells at a 1:5 ratio for 3 hours and stained for DNA (blue) and citrullinated  
831 histone H3 (green). Unstimulated neutrophils were used as controls.

832

Rodrigues et al. – Suppl. Figure 04



833

834

835 **S4 Fig.** (A) Representative westernblot images of total cell extracts of  
836 neutrophils incubated with infected (iRBC) or uninfected (cRBC) red blood cells  
837 at a 1:5 ratio. Westernblot was used for the detection of total PKC $\delta$  and  
838 phosphorylated Akt (p-Akt), JNK (p-JNK) and p38 (p-p38).  $\beta$ -actin was used as  
839 loading control. Unstimulated neutrophils were used as controls. (B and C)  
840 Human neutrophils were treated with SB239063 (SB, 20  $\mu$ M) (B) or SP600125  
841 (SP, 40  $\mu$ M) (C) for 30 minutes and then incubated with *P. falciparum*-infected  
842 red blood cells (iRBC) at a 1:5 ratio for 3 hours. NET production was  
843 determined by fluorimetry. Uninfected red blood cells (cRBC) were used as  
844 control. Data are presented as means  $\pm$  S.E.M. of the fold induction of


845 extracellular DNA signal relative to resting neutrophils. \*  $P < 0.05$  and \*\*  $P < 0.01$

846 relative to controls incubated with cRBC, #  $P < 0.01$  relative to untreated control.

847



Rodrigues et al. – Suppl. Figure 05



848

849

850 **S5 Fig.** (A) Murine neutrophils were treated with NAC (10  $\mu$ M) for 30 minutes  
851 and then incubated with *P. berguei* ANKA-infected red blood cells (iRBC). NET  
852 production was determined by fluorimetry. Uninfected red blood cells (cRBC)  
853 were used as control. Data are presented as means  $\pm$  S.E.M. of the fold  
854 induction of extracellular DNA signal relative to resting neutrophils. (B) Kinetics  
855 of ROS production by murine neutrophils incubated with infected red blood cells  
856 (iRBC) and treated or not with NAC. ROS production was evaluated by  
857 fluorimetry every 10 minutes for 30 minutes in the presence of CM-H2DCFDA.